SIGA Technologies To Present at The Wall Street Analyst Forum in New York City on February 11, 2002.Business Editors/Health and Medical Writers The Wall Street Analyst Forum's Institutional Investor Conference NEW YORK--(BUSINESS WIRE)--Jan. 30, 2003 SIGA Technologies, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : SIGA and FRANKFURT: SGW 919 473), a biopharmaceuticals company engaged in the discovery and development of novel products for the treatment of serious infectious diseases and who was recently awarded an initial U.S. Government contract with the U.S. Army for $1.6 million to develop an effective Smallpox antiviral drug, today announced that Tom Konatich, Acting CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and CFO See Chief Financial Officer. along with SIGA's Chief Scientific Officer, Dennis E. Hruby, Ph.D., will present to the investment community on Tuesday, February 11, 2003, at 11:40 AM EST EST electroshock therapy. EST abbr. electroshock therapy , at The Wall Street Analyst Forum's Institutional Investor Conference in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. at the Roosevelt Hotel. Analysts and portfolio managers who wish to attend the presentation should contact The Wall Street Analyst Forum at (802) 253-7596, or Dianne Will, Investor Relations for SIGA Technologies, at (518) 398-6222 to request additional information. Investors may access a live Internet webcast of the presentation through SIGA's website at: http://www.siga.com . A replay of the presentation will also be available on the Company's website for thirty days following the presentation. About SIGA SIGA is identifying and developing novel anti-infective agents based on its pioneering research in the field of bacterial surface proteins, structures used by bacteria to initiate and maintain an infection. Drug candidates that interfere with surface protein expression are expected to be effective against a wide range of disease-causing bacteria, including antibiotic resistant bacteria, by blocking the attachment of bacteria to human tissue, the first step in the infection process. By comparison, antibiotics available today act by interfering with either the structure or the metabolism of a bacterial cell, affecting its ability to survive and to reproduce. No currently available antibiotics target the attachment of a bacterium to its target tissue. Once prevented from attaching to and colonizing human tissue, bacteria are readily cleared by the body's immune system. SIGA's lead product development programs focus on biological warfare defense Noun 1. biological warfare defense - defense against biological warfare biological warfare defence, BW defence, BW defense defense, defensive measure, defence - (military) military action or resources protecting a country against potential enemies; "they , mucosal vaccines for strep throat and sexually transmitted diseases Sexually transmitted diseases Infections that are acquired and transmitted by sexual contact. Although virtually any infection may be transmitted during intimate contact, the term sexually transmitted disease is restricted to conditions that are largely , commensal commensal /com·men·sal/ (kom-men´sil) 1. living on or within another organism, and deriving benefit without harming or benefiting the host. 2. a parasite that causes no harm to the host. bacteria for the delivery of vaccines and protein therapeutics and novel antibiotics for gram positive and gram negative bacteria. This news release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such statements, including statements regarding the efficacy and intended utilization of SIGA's technologies under development, are not guarantees of future performance. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors which may cause such differences include the risk that potential products that appeared promising in early research or clinical trials to SIGA or its collaborators do not demonstrate efficacy or safety in subsequent pre-clinical or clinical trials, and the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market products tested in such trials |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion